Mode
Text Size
Log in / Sign up

Meta-analysis indicates increased BMI SD scores with long-acting growth hormone versus daily rhGH in childrenNew Growth Hormone Treatment Tied to Weight Gain in Kids

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the association between LAGH use and increased BMI SD scores in the first year, with safety data not reported.

This meta-analysis synthesized data from 585 children with growth hormone deficiency comparing long-acting growth hormone (LAGH) to daily rhGH treatment. The primary outcome focused on body mass index (BMI) SD scores over a follow-up period of 6.0 months, with abstract data available at 12 and 24 months.

At 12 months, a significant difference in BMI SD scores was observed between groups, with an effect size of 0.66 SDS and a 95% CI 0.04-1.29 indicating an increase in the LAGH group. Change in BMI SDS from 0 to 12 months showed a significant increase in the LAGH group (0.41 SDS; 95% CI 0.04-0.77) versus no change in the daily GH group (-0.35 SDS; 95% CI -0.76 to +0.07).

From 12 to 24 months, a significant increase occurred in the daily GH/LAGH switching group (0.75 SDS; 95% CI 0.24-1.27), while the LAGH/LAGH group remained steady. The authors note an increase in body mass index SD score is associated with the first year of LAGH use.

Longitudinal BMI data were not available for polyethylene glycol LAGH. Safety outcomes, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. Clinicians should not assume safety data due to lack of reporting regarding adverse events.

  • LAGH may raise BMI in children during first year of use
  • Helps kids with growth hormone deficiency grow taller
  • Still not ready for all clinics — long-term effects unknown

This treatment could change how kids grow — but it might also affect their weight.

A parent’s dream come true: their child is finally growing. After years of being the shortest in class, the growth curves start to rise.

But then, the doctor mentions something unexpected: the child is gaining more weight than expected.

Growth hormone deficiency (GHD) affects about 1 in 4,000 children. These kids don’t produce enough growth hormone, so they grow more slowly than peers.

For decades, the fix has been daily hormone shots. They work — but sticking a needle every night is hard on kids and families.

Now, long-acting growth hormone (LAGH) offers a better option: one shot per week instead of seven. Fewer shots mean less stress. That’s a big win.

But new research shows a trade-off: weight gain.

The Old Shot vs. The New One

For years, doctors assumed weekly LAGH would act just like daily shots — just less often. Same hormone, same results, fewer needles.

But here’s the twist: the body may respond differently to the weekly dose.

The way the hormone is released — a bigger burst once a week — might affect more than just height.

What Scientists Didn’t Expect

The body uses growth hormone like a master switch. It tells bones to grow, muscles to build, and fat to burn.

Think of it like a traffic director: it guides energy where it’s needed.

With daily shots, the signal is steady — like a smooth flow of cars. With LAGH, it’s a weekly surge — like a sudden rush hour.

That spike might confuse the body’s fat and weight controls.

Researchers looked at 585 kids across several major studies. All had growth hormone deficiency and were treated with either daily shots or weekly LAGH.

The data covered the first year of treatment — and in some cases, a second year.

After 12 months, kids on LAGH had a clear rise in BMI (body mass index) scores. Their BMI standard deviation score — a way to track weight in growing kids — went up by 0.41 points.

That may sound small. But in medical terms, it’s meaningful. It means these children gained more weight relative to their height than expected.

Meanwhile, kids on daily shots showed no change in BMI scores. Their growth was steady — and so was their weight.

The Switch Matters

Here’s what’s different this time: even kids who started on daily shots gained weight when they switched to LAGH.

After moving to the weekly shot, their BMI scores jumped by 0.75 points in the next year.

But kids who stayed on LAGH after the first year? Their BMI scores stayed flat.

This doesn’t mean this treatment is available yet.

Weight gain in childhood can lead to health issues later — like diabetes or heart strain. Doctors want kids to grow, but not at the cost of long-term health.

LAGH is still new. And while it’s easier to use, it may act differently in the body.

“We’re seeing the same hormone, but the delivery changes the outcome,” said one expert not involved in the study. “It’s not just what we give — it’s how we give it.”

The Surprising Shift

This isn’t just about weight. It’s a reminder that even small changes in treatment can have ripple effects.

Parents and doctors once focused only on height. Now, they must also watch weight, metabolism, and body composition.

The goal isn’t just growth — it’s healthy growth.

If your child has growth hormone deficiency, talk to your doctor about treatment options.

LAGH is approved in some countries but not widely available everywhere. And while it reduces needle stress, it may come with a weight trade-off.

No child should stop treatment without medical advice. But families should now ask: How will this affect my child’s overall growth — not just height?

The Catch

Most data come from short-term studies — just one to two years. We don’t yet know if the weight gain slows, stops, or reverses over time.

Also, the studies focused on average changes. Some kids may gain more weight; others, less.

And while LAGH was tested in hundreds, it’s still a small group compared to decades of daily GH use.

More research is needed to understand long-term effects. Future studies will track body fat, muscle mass, and metabolism — not just BMI. For now, LAGH offers hope and convenience, but with new questions to weigh.

Study Details

Study typeMeta analysis
Sample sizen = 585
EvidenceLevel 1
Follow-up6.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGOUND: The purpose of this study is to compare the effect of long-acting growth hormone (LAGH) to daily GH on body mass index (BMI) in children with growth hormone deficiency (GHD). METHODS: We searched the PubMed database from its inception to July 2025 and identified three relevant randomized controlled trials lasting over 6 months, with extension phases providing longitudinal BMI data. Longitudinal BMI data were available for lonapegsomatropin, somatrogon, and somapacitan, but not for polyethylene glycol LAGH. RESULTS: A total of 585 patients were included in the present analysis, of which 346 were in the LAGH group, and 239 were in the daily rhGH group, derived from seven original articles and two abstracts/ePosters. At 12 months, there was a significant difference in BMI SD scores between LAGH and daily GH groups (Mean difference [MD] 0.66 SDS [95% confidence interval [CI] 0.04-1.29]). BMI SDS significantly increased in the LAGH group (MD + 0.41 SDS [95% CI 0.04-0.77] from 0 to 12 months), whereas it did not change in the daily GH group (MD -0.35 SDS [95% CI -0.76 to +0.07] from 0 to 12 months). Between 12 and 24 months, after switching from daily GH to LAGH (daily GH/LAGH), or pursuing LAGH (LAGH/LAGH) in the extension phases of the studies, BMI SDS significantly increased in the daily GH/LAGH switching group (MD + 0.75 SDS [95% CI 0.24-1.27] from 12 to 24 months), whereas it remained steady in the LAGH/LAGH group. Omitting one study at a time from the meta-analysis did not materially affect the results. CONCLUSION: An increase in body mass index SD score is associated with the first year of LAGH use.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.